The UK’s National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending that the National Health Service provide Seagen’s Tukysa (tucatinib) as a treatment for patients with HER2-positive breast cancer.

NICE endorsed the drug in combination with Roche’s Herceptin (trastuzumab) and Xeloda (capecitabine) for breast cancer patients who have previously received two or more anti-HER2 treatments.

The institute previously rejected Tukysa over cost concerns. However, this time Seagen offered a confidential discount and provided additional efficacy data, especially in patients suffering from brain metastases.

NICE is expected to issue final guidance in March.